Background: There is a relationship between HCV infection and accumulation of body iron in the liver. Iron overload has been found to be cofactor for HCV associated fibrosis and hepatocellular carcinoma. Hepcidin produced by hepatocytes, is very important in regulation of iron metabolism. Disturbances in Hepcidin concentrations have been reported in chronic HCV infection and hepatocellular carcinoma. The aim of the work: is to measure levels of serum hepcidin in chronic hepatitis C patients and evaluate any association with the viral load after antiviral treatment. Aim of work:To measure hepcidin level in chronic hepatitis C patients (before and after treatment with antiviral drugs) and healthy controls to assess the level of hepcidin in CHC and its relation to antiviral therapy. Patient and methods: Our study was carried on 50 patients with chronic hepatitis C. Hepcidin levels were evaluated for Hepcidin before starting the antiviral therapy treatment (group A) andafter 24 weeks course of antiviral therapy(group B)with a commercially available enzyme-linked immunosorbent assay kits in addition to 20 apparently normal volunteers with matched age and sex as control group (group C). Results: Regarding serum Hepcidin, there was a highly statistical significant difference between patient and control group. Hepcidin levels in CHC patients were low in comparision to HCV-ve people. Highly statistical significant (p-value > 0.05) positive correlation (r = 0.67) between Hepcidin before and after treatment in patients group. Conclusion: Chronic HCV infection is associated with low level of serum hepcidin. That effect of HCV on hepcidin level was fully reversible after antiviral treatment.
Background: The prevalence of hepatitis C virus (HCV) in Egypt is quite high, and the combined oral direct-acting antiviral agents (DAAs) may have impressive results.Objectives: To assess the cardiovascular effects of oral antiviral treatment in non-cardiac HCV patients. Paitents and Methods:The study enrolled 100 patients with positive HCV who were enrolled for the new oral antiviral therapy in the form of Sofosbuvir and dclatsavir with or without ribavirin for 3 or 6 months. All patients on our study were subjected to follow up pre-and post-oral antiviral course, and the end point of the study was the development of a major cardiovascular event, e.g. congestive heart failure, echocardiographic evidence of left ventricular dysfunction, occurrence of significant arrhythmias, or acute coronary syndrome. The following parameters were accomplished: medical history and clinical examination, electrocardiogram, Echo-Doppler study, and laboratory investigations.Results: No significant differences were found between the patients regarding demographic criteria. None of the patients had developed any major cardiac event. No significant changes were observed regarding ST segment and T wave abnormalities, arrhythmias, or QT interval. None of patients developed echocardiographic regional wall motion abnormalities at baseline or at study end. Systolic function parameters showed minute non-significant changes over study visits. Diastolic function parameters showed non-significant changes between baseline and post oral antiviral course visit. Conclusion:The DAAs used in combination regimen didn't significantly affect the cardiovascular system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.